Evacetrapib (LY2484595)

Evacetrapib (LY2484595) (订货以英文为准)

编号:E128064
CAS号:1186486-62-3
分子式:C31H36F6N6O2
分子量:638.65
货号 品牌 包装 目录价 您的价格 库存 数量 购买
E128064-5mg 阿拉丁 5mg ¥399.90
E128064-100mg 阿拉丁 100mg ¥3999.90
E128064-25mg 阿拉丁 25mg ¥1399.90
产品名称 Evacetrapib (LY2484595)
中文名称 Evacetrapib (LY2484595)
CAS号 1186486-62-3
分子式(M.F.) C31H36F6N6O2
分子量(M.W.) 638.65
储存条件 -20°C储存
溶解性DMSO 12.8 mg/mL Water <1 mg/mL Ethanol 12.8 mg/mL
存贮条件储存温度-20°C
产品介绍Evacetrapib (LY2484595)是高活性CETP选择性抑制剂,IC50为5.5 nM,能在不增加醛固酮和血压的情况下提高高密度脂蛋白胆固醇。
生化机理Evacetrapib (LY2484595) inhibits human plasma CETP protein with IC50 of 26 nM. Evacetrapib (LY2484595) (< 10 μM) does not induce aldosterone or cortisol synthesis in H295R cells.Evacetrapib (LY2484595) (30 mg/kg, orally) results in 98.4%, 98.6%, and 18.4% inhibition of CETP activity at 4 hours, 8 hours and 24 hours post dose respectively in human ApoAI and CETP double transgenic mice. Evacetrapib (LY2484595) (30 mg/kg) results in 129.7% increase in HDL-C 8 hours after oral administration. The ED50 values of CETP inhibitory activity 8 hours post oral dosing for Evacetrapib (LY2484595) in two dose-response studies are calculated to be 3.5 mg/kg and 4.1 mg/kg respectively. Evacetrapib (LY2484595) (< 200 mg/kg) does not increase blood pressure in Zucker diabetic fatty rats.
别名LY2484595;LY 2484595;LY-2484595;反式-4-(((5S)-5-(((3,5-双(三氟甲基)苯基)甲基)(2-甲基-2H-四氮唑-5-基)氨基)-2,3,4,5-四氢-7,9-二甲基-1H-1-苯并氮杂卓-1-基)甲基)环己烷羧酸;;LY2484595;LY 2484595;LY-2484595;trans-4-(((5s)-5-(((3,5-bis(trifluoromethyl)phenyl)methyl)(2-methyl-2h-tetrazol-5-yl)amino)-2,3,4,5-tetrahydro-7,9-dimethyl-1h-1-benzazepin-1-yl)methyl)cyclohexanecarboxylic acid
搜索质检报告(COA)
搜索MSDS
相关产品
CAS号:27519-02-4
¥ 268.00 T-63624+1ml
CAS号:13389-42-9
¥ 232.00 M68521-1ML
CAS号:14919-01-8
¥ 251.00 M68518-1ML
CAS号:130-22-3
¥ 98.00 A835626-100ml
CAS号:2243-76-7
¥ 78.00 A835612-100ml
CAS号:23103-98-2
¥ 90.00 P816121-1ml
CAS号:1398-61-4
¥ 749.00 C805623-250mg
CAS号:75-27-4
¥ 185.00 B801896-2ml
CAS号:75-27-4
¥ 190.00 B801895-2ml